Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...
News Medical on MSN21h
Investigating the impact of CircRNAs on cancer progression and drug resistance
The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance.